Home » The Scan » Ah, the Promise

Ah, the Promise

Jun 24, 2009

GlaxoSmithKline's CEO Andrew Witty says that overhauling the company's drug discovery operation was a "major upheaval" but is now showing results. According to Reuters, Witty also says that in the last 15 years, the drug industry floundered by basing the discovery process on combinatorial chemistry, genomics, and proteomics. "These were all supposed to transform productivity yet none of them did.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Scan

When the Ailment You're Studying Becomes Personal

In an against-all-odds twist, a researcher studying exceeding rare FOXG1 mutations discovers her daughter has the syndrome.

Irish Genomics Initiative Looks to Expand Into Scotland

An effort by Genomics Medicine Ireland is creating a database of diseases based on the genomics of people in Ireland. It now is looking into the possibility of including Scotland in its work.

Another Source of Data for 23andMe

In recent weeks, the direct-to-consumer genetics firm has rolled out a health hub where customers can share information concerning 18 common health conditions.

This Week in PLOS

In PLOS this week, new genes associated with prostate cancer risk, genetic patterns in M. bovis, and more.

Sponsorships

Privacy Policy.  Copyright © 2018 GenomeWeb LLC.  All Rights Reserved.